Plain-English translation of NCT07135466 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new immunotherapy called SHB-04-CD22, which uses your own immune cells to fight certain blood cancers. Doctors will collect your immune cells, modify them in the laboratory to recognize and attack cancer cells, and then give them back to you as a single infusion. This approach is designed for patients whose cancer has come back or stopped responding to standard treatments, including other immune cell therapies.
Many patients with blood cancers eventually stop responding to current treatments, including a similar immune cell therapy that targets a different cancer marker. This trial is exploring whether targeting a different marker on cancer cells with this new treatment might help patients whose cancers are no longer responding to existing options.
You likely qualify if…
You likely don't qualify if…
You will have a one-time procedure to collect your immune cells through a process called apheresis (similar to donating blood plasma). The cells are then sent to a laboratory where they are modified genetically to recognize and fight your cancer. You will receive chemotherapy to prepare your body, followed by a single infusion of the modified cells back into your bloodstream. You will then be closely monitored for approximately three months with blood tests, genetic studies, and disease assessments to see how you respond and to watch for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Israel
Phase
Safety & dosing / Early efficacy
Sponsor
Sheba Medical Center
Enrollment target
~50 participants
Started
February 2026
Primary completion
April 2027
Age range
1 Year – 80 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Sivan Yakobi
Sheba Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.